AzTrials
AzTrials

Cancer, Digestive SystemNCT05646043

PREHAB - Improving Condition Before Surgery

A study testing Physical training and Muscle strength training in people with Cancer, Digestive System and Cancer, Rectum, run by University Hospital Ostrava at 1 site in Czechia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The pilot research project is focused on the feasibility of a prehabilitation program for two groups of diagnoses (esophageal and stomach cancer, rectal cancer). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cancer, Digestive System, Cancer, Rectum
What is being tested?
Physical training and Muscle strength training
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteCzechia
Study dates
1 Dec 2022to Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • radically operable locally advanced cancer of the esophagus, esophagogastric junction, stomach
  • radically operable locally advanced carcinoma of the rectum
  • the patient is able to handle the planned surgical resection procedure
  • planned preoperative neoadjuvant therapy
  • age > 18 years
  • the ability to complete a spiroergometric examination
  • the ability to carry out a prehabilitation program consent to participate in the study confirmed by signing the informed consent

Who cannot join

  • contraindications for spiroergometric examination
  • limitation on the part of the locomotor system to spiroergometric examination or daily exercise (e.g. amputation, severe gonarthrosis, coxarthrosis)
  • inoperability determined by the interdisciplinary team
  • inability to manage the planned operational performance
  • acute surgical performance
  • synchronous malignant disease
Show all 9Show fewer
  • multivisceral resection
  • planned non-surgical therapeutic procedure
  • incomplete data

Trial locations and contacts

1 site in 1 country.

Czechia1 site, 1 recruiting
  • University Hospital Ostrava

    Ostrava, Moravian-Silesian Region, 708 52

    Jiří Hynčica, 0042059737 ext. 2587, jiri.hyncica@fno.cz

    Irina Chmelová, MD,PhD,MBA

    Recruiting

Other trials in Czechia

About this study

Official title: PREHABILITATION During Neoadjuvant Therapy in Patients With Cancer of the Upper Digestive Tract and Rectum

The pilot research project is focused on the feasibility of a prehabilitation program for two groups of diagnoses (esophageal and stomach cancer, rectal cancer).

Read the detailed description

With the aim of achieving downstaging, downsizing, and reducing the risk of recurrence, neoadjuvant chemotherapy, possibly chemoradiotherapy - i.e. neoadjuvant therapy is indicated in the preoperative period for patients with cancer of the upper digestive tract and rectal cancer.

Chemotherapy has a negative impact not only on the overall physical and mental condition of the patient but also on the quality of life and on the daily activities of the individual, especially in the period when the organism is facing an abnormal stress load in the sense of extensive surgical procedures.

Recently, attention and efforts to improve postoperative morbidity and mortality have increasingly focused on the preoperative period. The concept of prehabilitation, which is defined as an intervention improving functional capacity before an upcoming physiological stressor, appears as a way to contribute to this. This fact is evidenced by a number of published references.

The main aim of the study is to confirm or refute the feasibility of the prehabilitation program during neoadjuvant therapy in two diagnostic groups of patients:

  • - Patients with cancer of the upper digestive tract
  • - Patients with rectal cancer

The prehabilitation program will be implemented in the patient's home environment.

The study aims to answer the basic research question of whether selected patients will be able to complete a home exercise regimen during the preoperative period when they will undergo neoadjuvant therapy.

As part of the study, the program's security and feasibility will be tested.

Being tested
Physical training, Muscle strength training
Keywords
prehabilitation, cancer of the digestive system, cancer of the rectum, endurance walking, power training
Medical subject headings
Digestive System Neoplasms, Rectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Physical trainingBehavioural

    Physical training consists of endurance walking and strength training. The basis for determining the number of steps per day is the baseline value of each patient. This will increase by 10-15% every week until the surgery date. The assumption of a total load increase is 120-180% compared to the baseline.

  • Muscle strength trainingBehavioural

    Muscle strength training will take place using exercises to strengthen the upper and lower limbs and to strengthen the trunk. There will be a set of 5 exercises in two difficulty variants. The study subjects will perform this set 7 days a week, and will repeat the assembly a total of two times. The total time of strength training is 10 min.

Study groups in NCT05646043
Study groupRoleWhat they receive
Patients with cancer of the digestive systemActive comparatorPatients with cancer of the digestive system (oesophageal and stomach cancer) will be enrolled in this study arm.
Receives: Behavioral: Physical training; Behavioral: Muscle strength training
Patients with cancer of the rectumActive comparatorPatients with cancer of the rectum will be enrolled in this study arm.
Receives: Behavioral: Physical training; Behavioral: Muscle strength training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of enrolled patients

    The number of patients who express an interest in being included in the study from all patients diagnosed and indicated for neoadjuvant therapy in the monitored period. the reasons for refusal to enroll in the study will be monitored.

    Measured: 3 months

  2. Number of patients completing the program

    The number of patients who complete the prehabilitation program by the time of surgery.

    Measured: 3 months

  3. Individual patient compliance

    Number of days when the patient wore the smart bracelet and performed or attempted to perform the exercise program out of the total number of days in the monitored period

    Measured: 3 months

Secondary outcomes (19)
  1. Changes in spirometry examination results

    Changes in spirometry examination will be assessed, comparing the baseline values with the values after training (maximum tidal volume (ml/1kg of weight/1 min), anaerobic threshold (beats/min).

    Measured: 3 months

  2. Changes in the quality of life

    Changes in the quality of life will be monitored using the EORTC Core Quality of Life questionnaire (EORTC QLQ-C30). This questionnaire is designed to measure cancer patients' physical, psychological and social functions.

    Measured: 3 months

  3. Parameters monitored by the oncologist

    Number of patients with chemotherapy dose reduction or premature termination of chemotherapy, number of patients with complete chemotherapy, number of patients hospitalized due to chemotherapy toxicity

    Measured: 3 months

  4. Exercise program - number of steps/day

    The number of steps taken by the study subjects in a day will be counted.

    Measured: 3 months

  5. Exercise program - pressing force on the dynamometer

    The pressing force on the dynamometer (in kg) will be assessed at the beginning and at the end of the program.

    Measured: 3 months

  6. Exercise program - InBody examination

    The InBody examination (analysis of body composition in %) will be performed at the beginning and at the end of the program.

    Measured: 3 months

  7. Exercise program - Body Mass Index

    The value of Body Mass Index will be recorded at the beginning and at the end of the program will be assessed (in kg/m2), changes will be assessed.

    Measured: 3 months

  8. Exercise program - perceived exertion

    The perceived exertion will be assessed using the Borg Rating of Perceived Exertion Scale (RPE). RPE is based on the physical sensations a person experiences during physical activity, including increased heart rate, increased respiration or breathing rate, increased sweating, and muscle fatigue. The rating is from 6 to 20.

    Measured: 3 months

  9. Parameters monitored by the anesthesiologist - ASA value

    ASA value - the ASA physical status classification system is a system for assessing the fitness of patients before surgery. It is a five-category physical status classification defined by the American Society of Anesthesiologists.

    Measured: 3 months

  10. Parameters monitored by the anesthesiologist - morbidity assessment

    Morbidity assessment among the study population will be performed, using assessment of incidence and prevalence.

    Measured: 3 months

  11. Parameters monitored by the anesthesiologist - preoperative analgesia

    The use of preoperative analgesia will be recorded and assessed.

    Measured: 3 months

  12. Parameters monitored by the anesthesiologist - postoperative opioid analgesia

    The use of postoperative opioid analgesia will be recorded and assessed.

    Measured: 3 months

  13. Parameters monitored by the anesthesiologist - pain assessment

    The Numeric Pain Rating Scale will be used to assess pain. The Numeric Pain Rating Scale is a unidimensional measure of pain intensity in adults, including those with chronic pain due to rheumatic diseases.

    Measured: 3 months

  14. Laboratory examinations - complete blood count

    Complete blood count will be analyzed (g/L).

    Measured: 3 months

  15. Laboratory examinations - CRP values

    C-Reactive Protein (CRP) will be assessed (in mg/L). C-reactive protein (CRP) is an acute phase protein that is produced in the liver. The levels increase rapidly in response to acute inflammation.

    Measured: 3 months

  16. Laboratory examinations - procalcitonin level

    Procalcitonin levels will be analyzed (ng/L). This marker indicates the presence of infection.

    Measured: 3 months

  17. Laboratory examinations - nutritional parameters

    Nutritional parameters - the levels of total protein, albumin and prealbumin will be analyzed (mg/dL).

    Measured: 3 months

  18. Laboratory examinations - coagulation factors (aPTTp

    Coagulation factors - Activated Partial Thromboplastin Time (APTT) will be measured (in seconds).

    Measured: 3 months

  19. Laboratory examinations - coagulation factors (fibrinogen)

    Coagulation factors - fibrinogen levels will be assessed (mg/dL). Higher and lower levels point to blood clotting disorders.

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Dec 2022
  2. Study start1 Dec 2022
  3. Primary completionNov 2025 (estimated)
  4. Study completionDec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
The study subjects will be enrolled in two parallel groups.
Masking
None (open label)
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05646043
Sponsor's protocol ID
08/RVO-FNOs/2022
Status last verified
Jan 2024
First submitted
15 Nov 2022
Last updated
18 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: There is no plan to make individual participant data available to other researchers. The data may be provided upon request.

Publications

  • Chmelova I, Pastucha D, Hudecek T, Guran Z, Ciecotkova S, Martinek L, Zubikova J, Matlova A, Dolezel J, Salounova D, Chmelo J. Prehabilitation during neoadjuvant therapy in patients with cancer of the upper gastrointestinal tract and rectum-the study protocol. Front Sports Act Living. 2025 Feb 3;6:1495398. doi: 10.3389/fspor.2024.1495398. eCollection 2024.

    PubMed 39963182

Questions about this trial

What is this clinical trial studying?

A study testing Physical training and Muscle strength training in people with Cancer, Digestive System and Cancer, Rectum, run by University Hospital Ostrava at 1 site in Czechia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jiří Hynčica (0042059737 ext. 2587, jiri.hyncica@fno.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of enrolled patients (time frame: 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05646043, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in